값202020212022202320242025TTM판매비·일반관리비———————연구개발———————영업 이익———————비영업 수익, 합계———————이자비용(자본화한 이자 차감 후)———————이자비용을 제외한 비영업 수익———————비정상 수입/지출———————세전소득———————지분법 손익———————세금———————비지배 지분———————세후 기타 수익/비용———————중단된 사업 부문 제외 순이익———————중단된 사업———————순이익———————희석보정———————우선배당———————보통주주에게 귀속되는 희석 순이익———————주당 순이익(기본 EPS)———————희석 주당 순이익 (희석 EPS)———————평균 발행주식수———————희석주식수———————EBITDA———————EBIT———————매출원가———————기타 매출원가———————감가상각 및 무형자산 상각 (현금흐름)———————
Grifols, S.A. - American Depositary Shares
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care.